Scholarlink

Objective <p>The purpose of this study was to investigate the predictive relevance of CD27 and CD117 expression and the prognostic value in newly diagnosed multiple myeloma (NDMM) patients.</p> Methods <p>This retrospective cohort study analyzed 160 newly diagnosed multiple myeloma (NDMM) patients at Beijing Chaoyang Hospital (2016–2023), evaluating CD27 (TNF receptor family member regulating plasma cell differentiation) and CD117 (c-KIT proto-oncogene product mediating hematopoietic cell survival) expression patterns via pretreatment flow cytometry. Patients were stratified by CD27/CD117 membrane positivity to assess their combined prognostic significance on disease progression, with survival outcomes tracked through standardized clinical surveillance protocols.</p> Results <p>The CD27 negative cohort demonstrated severe disease burden, evidenced by elevated β2-MG, increased bone marrow plasma cell infiltration, reduced hemoglobin levels, percentage of high ISS III. Kaplan-Meier analysis demonstrated that CD27 positive cohort showing significantly prolonged median PFS versus CD27 negative counterparts (78 vs. 33 months, <i>P</i> = 0.0078). While CD117 alone lacked prognostic significance, combined CD27(+)CD117(+) status was associated with superior PFS (<i>P</i> = 0.0041 vs. subgroups), earlier ISS\MASS staging (<i>P</i> = 0.005, <i>P</i> = 0.021), deeper therapeutic remission rates(Protease inhibitor-based therapy, <i>P</i> = 0.009), and lower frequency of high-risk cytogenetic abnormalities compared to all other combinations, and particularly outperforming CD27(−)CD117(−) patients. Among CD27-expressing patients, CD117 positive patients had better survival performance (<i>P</i> = 0.0424). Multivariate Cox regression confirmed CD27 positivity as an independent protective factor (HR 0.50, <i>P</i> = 0.009) and thrombocytopenia (PLT &lt; 150 × 10⁹/L) as a risk predictor (HR 2.28, <i>P</i> = 0.002), both maintaining significance after adjusting for conventional parameters.</p> Conclusion <p>CD27 positive patients have a better prognosis, and the combination of CD27 and CD117 allows refined prognostic risk stratification of MM patients. The expression of CD27 and CD117 is associated with improved prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月19日

查看全文
  • Xu Si,
  • Jing Zhao,
  • Yichuan Song,
  • Wenxuan Fu,
  • Rui Zhang

摘要

Objective

The purpose of this study was to investigate the predictive relevance of CD27 and CD117 expression and the prognostic value in newly diagnosed multiple myeloma (NDMM) patients.

Methods

This retrospective cohort study analyzed 160 newly diagnosed multiple myeloma (NDMM) patients at Beijing Chaoyang Hospital (2016–2023), evaluating CD27 (TNF receptor family member regulating plasma cell differentiation) and CD117 (c-KIT proto-oncogene product mediating hematopoietic cell survival) expression patterns via pretreatment flow cytometry. Patients were stratified by CD27/CD117 membrane positivity to assess their combined prognostic significance on disease progression, with survival outcomes tracked through standardized clinical surveillance protocols.

Results

The CD27 negative cohort demonstrated severe disease burden, evidenced by elevated β2-MG, increased bone marrow plasma cell infiltration, reduced hemoglobin levels, percentage of high ISS III. Kaplan-Meier analysis demonstrated that CD27 positive cohort showing significantly prolonged median PFS versus CD27 negative counterparts (78 vs. 33 months, P = 0.0078). While CD117 alone lacked prognostic significance, combined CD27(+)CD117(+) status was associated with superior PFS (P = 0.0041 vs. subgroups), earlier ISS\MASS staging (P = 0.005, P = 0.021), deeper therapeutic remission rates(Protease inhibitor-based therapy, P = 0.009), and lower frequency of high-risk cytogenetic abnormalities compared to all other combinations, and particularly outperforming CD27(−)CD117(−) patients. Among CD27-expressing patients, CD117 positive patients had better survival performance (P = 0.0424). Multivariate Cox regression confirmed CD27 positivity as an independent protective factor (HR 0.50, P = 0.009) and thrombocytopenia (PLT < 150 × 10⁹/L) as a risk predictor (HR 2.28, P = 0.002), both maintaining significance after adjusting for conventional parameters.

Conclusion

CD27 positive patients have a better prognosis, and the combination of CD27 and CD117 allows refined prognostic risk stratification of MM patients. The expression of CD27 and CD117 is associated with improved prognosis.